Vasoactive Peptides in Portal Pressure
Information source: Bayside Health
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Portal Hypertension
Intervention: Norfloxacin (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Bayside Health Official(s) and/or principal investigator(s):
William W Kemp, MBBS, FRACP, Principal Investigator, Affiliation: The Alfred
Overall contact:
William W Kemp, MBBS, FRACP, Phone: 92762000, Ext: 3327, Email: w.kemp@alfred.org.au
Summary
This study is looking at the detection of vasoactive peptides in portal hypertension.
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- HVPG >= 12 mmHg
Locations and Contacts
William W Kemp, MBBS, FRACP, Phone: 92762000, Ext: 3327, Email: w.kemp@alfred.org.au
Alfred Hospital, Melbourne, Victoria 3181, Australia; Recruiting
William W Kemp, MBBS, FRACP, Phone: 92762000, Ext: 3327, Email: w.kemp@alfred.org.au
Additional Information
Last updated: July 25, 2007
|
